Health TrialsbyHealthPanel

Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

ConditionHodgkin Lymphoma in Remission
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

About this trial

Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics:

* in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma

Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy

Patients of both sexes aged ≥ 18 years at enrollment

Signature of informed consent

Disqualifiers

Concomitant second neoplasm

Trial design

Design model

Single group

Treatments tested in this trial

  • peripheral blood sampling

    Other intervention

    It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics: * in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage II b, III or IV, Ann Arbor Classification).

Treatment groups

200 Participants
are divided into 1 treatment group
Group A: hodgkin lymphoma patients in complete remission for at least two years and newly diagnosedExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA)

Determine the biological age of patients

Time frame
through study completion, an average of 2 year
2

DNA methylation (methylation rate)

Determine the biological age of patients

Time frame
through study completion, an average of 2 year

Secondary outcomes

1

evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA)

Determine the possible acceleration of the biological age of patients

Time frame
through study completion, an average of 2 year
2

DNA methylation (methylation rate)

Determine the possible acceleration of the biological age of patients

Time frame
through study completion, an average of 2 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Lead sponsor

Source ClinicalTrials.gov
Apply now